公开(公告)号：EP4190323A1

公开(公告)日：2023-06-07

申请号：EP21856175.1

申请日：2021-08-10

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi-Rang

IPC分类号： A61K31/197 ,  A61K31/138 ,  A61K31/522 ,  A61P25/28 ,  A23L33/10

摘要： The present invention relates to a pharmaceutical composition comprising calcium pantothenate, or calcium pantothenate and dimenhydrinate as active ingredients for prevention and treatment of myopathy. According to the present disclosure, calcium pantothenate upregulates the expression of MHC, myogenin 4-EBP, and p70S6K to promote myoblast differentiation and myogenesis, thereby prolonging the duration of life in amyotrophic lateral sclerosis patients and promoting the growth of MSC in Duchenne muscular dystrophy mice. Such effects are synergistically increased upon combined treatment with dimenhydrinate. Thus, they can be advantageously used for preventing or treating myopathy.

公开(公告)号：EP4394779A1

公开(公告)日：2024-07-03

申请号：EP22873185.7

申请日：2022-09-22

申请人： Oncocross Co., Ltd.

发明人： LEE, Young Heun ,  KIM, Yi Rang ,  KANG, Ji Hoon

IPC分类号： G16B40/20 ,  G16B25/10 ,  G16B30/10 ,  C12Q1/6886 ,  G01N33/574 ,  G16B35/00 ,  G16B50/00

CPC分类号： C12Q1/6886 ,  G01N33/574 ,  G16B25/10 ,  G16B40/20 ,  G16H50/20

摘要： A method for diagnosing cancer of unknown primary site by using artificial intelligence is disclosed. A method for diagnosing cancer of unknown primary site by using artificial intelligence, according to one embodiment of the present invention, includes the steps of: generating gene expression pattern information of a sample collected from tissue in which metastatic cancer has occurred; removing gene expression pattern information derived from pre-learned tissue from the gene expression pattern information of the sample collected from the tissue in which the metastatic cancer has occurred; comparing the gene expression pattern information from which the gene expression pattern information derived from the tissue has been removed with pre-learned gene expression pattern information for each cancer type; and specifying a primary site of the sample collected from the tissue in which the metastatic cancer has occurred.

公开(公告)号：EP3342408A1

公开(公告)日：2018-07-04

申请号：EP16842181.6

申请日：2016-08-24

申请人： Oncocross Co. Ltd.

发明人： CHOI, Jin Woo

IPC分类号： A61K31/352 ,  A61K31/35

CPC分类号： A61K31/35 ,  A61K31/352

摘要： A pharmaceutical composition for preventing and treating liver diseases, includes cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.

公开(公告)号：EP4321161A1

公开(公告)日：2024-02-14

申请号：EP22784860.3

申请日：2022-03-31

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi Rang

IPC分类号： A61K31/4375 ,  A61K31/352 ,  A61P13/12 ,  A23L33/10

摘要： The present disclosure relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxyphenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one in treating kidney disease. According to the present disclosure, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one of the present disclosure palliates clinical symptoms and alleviates renal failure and renal injury through reduction of blood glucose levels and insulin resistance in diabetic nephrosis animal models. Thus, the compound may be advantageously applied to a use for preventing or treating kidney diseases, especially diabetic renal diseases.

公开(公告)号：EP4321160A1

公开(公告)日：2024-02-14

申请号：EP22784859.5

申请日：2022-03-31

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi Rang

IPC分类号： A61K31/4375 ,  A61K31/352 ,  A61P3/10 ,  A23L33/10

摘要： The present invention relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxyphenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one for treating diabetes. According to the present invention, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one of the present invention alleviates clinical symptoms of diabetes, reduces blood sugar, reduces blood glucose concentrations and insulin-resistance and reduces liver and kidney damages in an animal model of insulin-resistant diabetes, and thus can be effectively used for preventing or treating diabetes, especially insulin-resistant diabetes.

公开(公告)号：EP4331587A1

公开(公告)日：2024-03-06

申请号：EP22796144.8

申请日：2022-04-27

申请人： Oncocross Co., Ltd. ,  Jeil Pharmaceutical Co., Ltd.

发明人： KIM, Yi Rang ,  PARK, Sang Yun ,  YANG, Ga Eul

IPC分类号： A61K31/5377 ,  A61P3/00 ,  A61P3/04 ,  A61P1/16 ,  A61P35/00

摘要： The present invention relates to a composition for preventing or treating metabolic diseases, containing 10-ethoxy-8-(morpholinomethyl)-2,3,4,6-tetrahydrobenzo[h][1,6]naphthyridin-5(1H)-one, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a salt hydrate thereof as an active ingredient. Due to an adipocyte differentiation inhibitory effect, a fat accumulation inhibitory effect, an NAFLD inhibitory effect, and an NASH-induced fibrosis inhibitory effect of the composition, it is possible to prevent or treat metabolic diseases including nonalcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, nonalcoholic fatty liver (NAFL), and NAFLD-associated liver fibrosis, fatty liver, and obesity.

公开(公告)号：EP4306110A1

公开(公告)日：2024-01-17

申请号：EP22767339.9

申请日：2022-02-07

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi-Rang

IPC分类号： A61K31/44 ,  A61K31/352 ,  A61P3/00 ,  A61P1/16 ,  A23L33/10

摘要： The present invention relates to a composition for the treatment of metabolic diseases, containing torsemide and cromolyn. According to the present invention, if torsemide and cromolyn are used in combination, compared to when cromolyn alone is used, weight is reduced, insulin resistance is reduced and liver fat accumulation is remarkably reduced in a NASH animal model, and thus the present invention can be effectively used in the prevention or treatment of metabolic diseases including diabetes, obesity, insulin resistance and metabolic liver diseases.

公开(公告)号：EP3607949A1

公开(公告)日：2020-02-12

申请号：EP19789574.1

申请日：2019-04-17

申请人： Oncocross Co., Ltd.

发明人： KIM, Yi-Rang ,  CHOI, Jin-Woo

IPC分类号： A61K31/522 ,  A61K31/437 ,  A61K31/197 ,  A61P21/00 ,  A23L33/10

摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.